Summary
Gertrude B. Elion's "Selective Inhibitors of Dihydrofolate Reductase" centers on the development and application of compounds that specifically target and inhibit the enzyme dihydrofolate reductase (DHFR) in various organisms. The core thesis is that by designing inhibitors that preferentially bind to the DHFR of pathogens or rapidly dividing cells (like cancer cells), therapeutic agents can be created with significantly reduced host toxicity. This selectivity allows for effective treatment of diseases by disrupting essential metabolic pathways in the target organism or cell.
The book details the biochemical basis for DHFR inhibition, the structural requirements for selective binding, and the preclinical and clinical findings supporting the efficacy of these inhibitors. Readers gain an understanding of how medicinal chemistry and pharmacology can be combined to create highly targeted drugs, exemplified by the development of antifolates for treating infections and cancer. The work highlights the impact of rational drug design on the creation of life-saving medications.
Full text isn't indexed yet — this overview draws on general knowledge of the book and its metadata, and chat works the same way.
Key concepts
- Dihydrofolate Reductase (DHFR) — An enzyme crucial for the synthesis of purines and pyrimidines, essential building blocks for DNA and RNA.
- Antifolates — Drugs that inhibit the activity of DHFR, thereby blocking DNA synthesis and cell replication.
- Selective Toxicity — The principle of designing drugs that harm target organisms or cells (e.g., pathogens, cancer cells) while causing minimal damage to the host.
- Methotrexate — A well-known antifolate drug that competitively inhibits DHFR, used in chemotherapy and immunosuppression.
- Trimethoprim — An antibacterial agent that selectively inhibits bacterial DHFR, often used in combination with sulfamethoxazole.